GlassScriptPhysician profile
Alexander Alperovich
NPI 1922096221
$13,469.86
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,338 · 2020: $2,014 · 2021: $866 · 2022: $1,926 · 2023: $3,620 · 2024: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,705 · Travel and Lodging: $1,585 · Education: $35.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,704.93 |
| Travel and Lodging | $1,585.46 |
| Education | $35.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,785.02 | 2019-2024 | Impella |
| Siemens Medical Solutions USA, INC. | $2,085.33 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,430.72 | 2019-2024 | Lifevest |
| Pfizer INC. | $1,071.60 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $948.01 | 2019-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $842.10 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $694.44 | 2019-2023 | Farxiga |
| Amgen INC. | $667.83 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $472.62 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.64 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $296.80 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $278.04 | 2022-2024 | Onpattro, Amvuttra |
| Merck Sharp & Dohme LLC | $246.97 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $183.62 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $109.79 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $101.79 | 2022 | |
| Novo Nordisk INC | $84.67 | 2023 | Ozempic, Rybelsus |
| Bardy Diagnostics, INC. | $81.00 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $70.86 | 2019 | |
| Penumbra, INC. | $60.99 | 2022 | |
| Esperion Therapeutics, INC. | $58.30 | 2021-2023 | Nexletol |
| Ge Healthcare | $51.26 | 2019-2020 | |
| Angiodynamics, INC. | $47.99 | 2021-2022 | |
| Philips North America LLC | $41.80 | 2020-2023 | |
| Boston Scientific Corporation | $38.90 | 2019-2023 | Watchman Flx |
| Irhythm Technologies, INC. | $34.76 | 2019-2022 | |
| Medtronic Vascular, INC. | $34.50 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $32.62 | 2022 | |
| Abbott Laboratories | $21.01 | 2022 | |
| Aegerion Pharmaceuticals, INC. | $18.75 | 2019 | |
| Vital Connect, INC | $18.69 | 2024 | Vitalpatch Rtm |
| Lexicon Pharmaceuticals, INC. | $17.49 | 2023 | Inpefa |
| Medtronic, INC. | $17.14 | 2021 | |
| G Medical Diagnostic Services, INC. | $15.13 | 2021 | |
| Chiesi USA, INC. | $14.74 | 2019 | |
| Daxor Corporation | $13.80 | 2023 | Bva-100 |
| Scpharmaceuticals INC. | $12.77 | 2023 | |
| Elutia, INC. | $11.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Alperovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.